Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chunmeng Wang, Zhiqiang Wu, Yao Wang, +12

Clinical Cancer Research

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Yao Wang, Meixia Chen, Zhiqiang Wu, +11

OncoImmunology

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai, Zhiqiang Wu, Hejin Jia, +11

Journal of Hematology & Oncology

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

Kaichao Feng, Yang Liu, Yelei Guo, +6

Protein & Cell

Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic Rats

Yiling Si, Yali Zhao, Haojie Hao, +7

Diabetes

ImmunologyBiomedical EngineeringInsulin SignalingRegenerative MedicineMetabolic Syndrome +22

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

Kaichao Feng, Yelei Guo, Hanren Dai, +4

Science China Life Sciences

ImmunologyImmunoeditingPathologyPeripheral BloodImmunotherapeutics +14

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma

Chuan Tong, Yang Liu, Xingyu Ji, +11

Blood

Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers

Yelei Guo, Kaichao Feng, Yang Liu, +6

Clinical Cancer Research

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

Kaichao Feng, Yelei Guo, Yang Liu, +6

Journal of Hematology & Oncology

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Yao Wang, Chuan Tong, Hanren Dai, +12

Nature Communications